Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 392

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 392
---
 14, 
 2024 through 
 December 31, 
         2024 |   |     |              |      For the 
  period from 
   January 1, 
 2024 through 
 February 13, 
         2024 |   |     |              |      For the 
   year ended 
 December 31, 
         2023 |   |
|:-----------------------------------------------------------|:----|:-----------|-------------:|:--|:----|:-------------|-------------:|:--|:----|:-------------|-------------:|:--|
|                                                            |     | -Successor |              |   |     | -Predecessor |              |   |     | -Predecessor |              |   |
| Operating expenses:                                        |     |            |              |   |     |              |              |   |     |              |              |   |
| Research and development                                   |     | $          |    6,315,552 |   |     | $            |      764,192 |   |     | $            |    5,288,580 |   |
| General and administrative                                 |     |            |    8,985,351 |   |     |              |      132,941 |   |     |              |    2,386,469 |   |
| Total operating expenses                                   |     |            |   15,300,903 |   |     |              |      897,133 |   |     |              |    7,675,049 |   |
| Loss from operations                                       |     |            |  (15,300,903 | ) |     |              |     (897,133 | ) |     |              |   (7,675,049 | ) |
| Other income (expenses):                                   |     |            |              |   |     |              |              |   |     |              |              |   |
| Gain from settlement of liabilities with vendors           |     |            |    3,339,223 |   |     |              |            - |   |     |              |        8,144 |   |
| Other expenses                                             |     |            |     (672,378 | ) |     |              |            - |   |     |              |      (62,182 | ) |
| Change in fair value of earnout and derivative liabilities |     |            |    4,880,000 |